Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease and currently being evaluated in multiple types of cancer and for other serious diseases.

Type of Molecule

Small Molecule



Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Chronic Graft versus Host Disease (cGVHD) US, EU
Diffuse Large B-cell Lymphoma (DLBCL) US, EU
Phase 3
Follicular Lymphoma (FL) US, EU
Phase 3
Relapsed/Refractory Marginal Zone Lymphoma (MZL) US, EU
Pancreatic Cancer US, EU
Phase 3
Solid Tumors US, EU
Phase 2